Home > Riviste > Minerva Biotecnologica > Fascicoli precedenti > Minerva Biotecnologica 2014 December;26(4) > Minerva Biotecnologica 2014 December;26(4):223-33

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

MINERVA BIOTECNOLOGICA

Rivista di Biologia Molecolare e Biotecnologie


Indexed/Abstracted in: EMBASE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,25


eTOC

 

ORIGINAL ARTICLES  FREEfree


Minerva Biotecnologica 2014 December;26(4):223-33

Copyright © 2014 EDIZIONI MINERVA MEDICA

lingua: Inglese

Design of a chimeric DNA vaccine against Brucella spp.

Abkar M. 1, Lotfi A. S. 2, Amani J. 3, Ghorashi S. A. 4, Brujeni G. N. 5, Kamali M. 6

1 Department of Molecular Genetics, Faculty of Basic Sciences, Tarbiat Modares University, Tehran, Iran; 2 Department of Clinical Biochemistry, Faculty of Medicine, Tarbiat Modares University, Tehran, Iran; 3 Applied Microbiology Research Center, Baqiyatallah Medical Science University, Tehran, Iran; 4 School of Animal and Veterinary Sciences, Charles Sturt University, Australia; 5 Department of Microbiology & Immunology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran; 6 Nanobiotechnology Research Center, Baqiyatallah Medical Science University, Tehran, Iran


FULL TEXT  


Brucellosis, a common illness between domestic animals and humans, is mostly caused by Brucella (B) abortus, B. melitensis and B.suis. It has been shown vaccination of mice by Omp19 and Omp31 can induce protection against different Brucella spp. Furthermore, urease enzyme is considered a virulence factor in most members of Brucella. Here, we designed a chimeric DNA vaccine containing omp19, omp31 and urease genes to obtain high protection against Brucella spp. The construct was analyzed using bioinformatics tools. Linear and discontinuous B-cell epitopes, MHC class I and II binding peptides of the chimeric vaccine were predicted. Results suggest the construct can be an appropriate vaccine candidate against brucellosis.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail